ECTE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ECTE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-26), Echo Therapeutics's share price is $0.0002. Echo Therapeutics's Tangible Book per Share of Sep. 2016 for the quarter that ended in Sep. 2016 was $-0.57. Hence, Echo Therapeutics's Price to Tangible Book Ratio of today is .
The historical rank and industry rank for Echo Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
A closely related ratio is called PB Ratio. As of today, Echo Therapeutics's share price is $0.0002. Echo Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2016 was $-0.55. Hence, Echo Therapeutics's P/B Ratio of today is .
The historical data trend for Echo Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Echo Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | 11.91 | 80.00 | 3.81 | - | - |
Echo Therapeutics Quarterly Data | ||||||||||||||||||||
Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | - | - | - | - | - |
For the Medical Devices subindustry, Echo Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Echo Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Echo Therapeutics's Price-to-Tangible-Book falls into.
Echo Therapeutics's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Sep. 2016 ) |
= | 0.0002 | / | -0.57 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Echo Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael M Goldberg | director | C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Uri Landesman | 10 percent owner | 230 PARK AVENUE, NEW YORK NY 10169 |
Platinum Partners Value Arbitrage Fund, Lp | 10 percent owner | 250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019 |
Mark Nordlicht | 10 percent owner | 250 WEST 55TH STREET, NEW YORK NY 10019 |
Platinum Management (ny) Llc | 10 percent owner | 250 WEST 55TH STREET, NEW YORK NY 10019 |
Platinum-montaur Life Sciences, Llc | 10 percent owner | 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Platinum Partners Liquid Opportunity Master Fund L.p. | 10 percent owner | 152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019 |
Platinum Liquid Opportunity Management (ny) Llc | 10 percent owner | 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Bernhardt Charles Thomas Iii | officer: Interim CFO | 23 BIRCH ROAD, MALVERN PA 19355 |
Vincent D Enright | director | ONE CORPORATE CENTER, RYE NY 10580 |
William Grieco | director | 830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Robert F Doman | director, officer: EXEC. CHAIRMAN AND INTERIM CEO | C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887 |
Patrick T Mooney | director, officer: CEO AND PRESIDENT | C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038 |
Christopher P. Schnittker | officer: CFO | 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.